Statistics on Biotechnology Use  
Results by fields of operation
Company sector.  Biotechnology results by main variables by whichever Biotechnology activities are the main ones, secondary or a tool necessary for production
Unidades: specified in variables

;Total;Main;Secondary dwellings;Tool;
Companies that carry out R&D in Biotechnology;1.198;644;171;383;
%Companies according to biotechnology used: Genetic code;33,3;40,9;24;24,8;
%Companies according to biotechnology used: Functional units;39,8;44,2;38,1;33,3;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;24,2;28,8;14,2;20,8;
%Companies according to biotechnology used: Bioprocesses;49,6;42,6;52,3;60,2;
%Companies according to biotechnology used: Sub-cellular organisms;6,7;8,7;5,8;3,6;
%Companies according to biotechnology used: Bio-computing;23,9;33,5;13;12,7;
%Companies according to biotechnology used: Nanobiotechnology;11,2;14,5;13,4;4,7;
%Companies according to biotechnology used: Other;14,6;14,4;19,9;12,6;
%Company by field(s) of ultimate application of biotechnology use: Human Health;47,3;62,8;35,1;26,7;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;19,4;21,7;17,8;16,2;
%Company by field(s) of ultimate application of biotechnology use: Food products;32,5;26,1;30,5;44,1;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;24,1;20,7;31,8;26,5;
%Company by field(s) of ultimate application of biotechnology use: Environment;14,9;12,8;28,9;12,3;
%Company by field(s) of ultimate application of biotechnology use: Industry;12,8;12,8;17,8;10,6;
Personnel in R&D in biotechnology (no. of persons);13.615;8.038;1.812;3.765;
Personnel in R&D in biotechnology (no. of persons): Researchers;7.436;4.561;1.031;1.845;
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;6.178;3.477;781;1.920;
Personnel in R&D in biotechnology (no. of persons): women;7.639;4.718;918;2.003;
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;4.095;2.582;540;973;
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;3.544;2.136;378;1.030;
Personnel in R&D in biotechnology (FTE);9.365,2;5.985,1;1.120,4;2.259,7;
Personnel in R&D in biotechnology (FTE): Researchers;5.410,6;3.550,1;695,8;1.164,8;
Personnel in R&D in biotechnology (FTE): Technicians and assistants;3.954,6;2.435;424,6;1.095;
Personnel in R&D in biotechnology (FTE): women;5.385,8;3.561,4;597,6;1.226,7;
Personnel in R&D in biotechnology (FTE): (women) Researchers;3.032,9;2.028,8;372,1;632;
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;2.352,9;1.532,6;225,6;594,7;
Internal expenditure on R&D (thousands of euros);940.230;671.106;84.012;185.112;
1) By nature of the expense: Current expenses;871.813;624.784;75.356;171.672;
1.1) Remuneration to researchers;284.936;194.490;33.985;56.460;
1.2) Remuneration to technicians and assistants;148.254;96.140;14.239;37.875;
1.3) Other current expenses;438.623;334.154;27.132;77.337;
2) By nature of the expense: Capital expenses;68.417;46.322;8.656;13.440;
2.1) Land and buildings;11.763;6.204;2.874;2.685;
2.2) Equipment and instruments;39.641;24.588;5.378;9.674;
2.3) Acquisition of specific R+D software;2.831;1.735;319;777;
2.4) Otros productos de propiedad intelectual específicos para I+D;14.183;13.794;85;303;
1.1) By origin of the funds: Own funds;577.287;421.224;39.177;116.886;
1.2) By origin of the funds: From companies;142.672;96.993;8.211;37.467;
1.3) By origin of the funds: Public Administration funds;102.630;64.741;18.219;19.670;
1.4) By origin of the funds: From Universities;457;453;0;5;
1.5) By origin of the funds: From non profit private institutions;9.631;8.141;195;1.294;
1.6) By origin of the funds: Foreign funds;107.553;79.554;18.210;9.790;
Purchase of R&D services in biotechnology (thousands of euros);114.839;87.621;15.855;11.363;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;69.258;50.862;13.073;5.324;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;45.581;36.760;2.782;6.039;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;41,8;48,5;36,1;33;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;12;9,3;16,6;14,5;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;13,1;11,5;15;14,8;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;10,7;10,8;10,3;10,5;
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of access to international markets;15;16;15;14;
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of distribution and sales channels;16;18;16;12;
%Companies that consider the following obstacles as very important considering biotechnology development : Acceptance / public perception;16;15;19;17;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;37;41;38;31;
%Companies that consider the following obstacles as very important considering biotechnology development : Time / cost;51;56;50;43;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;19;17,4;18,9;21,8;
% Companies that have requested biotechnology patents;18;26;14;8;
Number of patents requested;643;471;54;118;
% Companies with income of an international origin related to biotechnological activities;24,4;30,7;15,3;17,9;
% Turnover representing income of an international origin related to biotechnological activities;1,6;8,5;0;1,5;
% Income of of an international origin related to biotechnological activities distributed in: Income received from the EU;56;61;60;40;
% Income of of an international origin related to biotechnological activities distributed in: Income received from other countries;44;39;40;60;
% Income of of an international origin related to biotechnological activities by classification: Internacional trade in products and services;70;79;73;44;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;23,9;18,5;0,5;41,4;
% Income of an international origin related with activities according to the classification: Operating source abroad;5,3;1,9;26,7;14,5;
% Income of an international origin related with activities according to the classification: Other;0,6;0,8;0;0,1;
Notas:
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute